FOLH1 and prostate cancer: Ga68 PSMA PET-CT has the capacity to revolutionize the diagnostic paradigm by providing clinicians with unprecedented insights into disease extent and treatment response, potentially reshaping therapeutic decision making in prostate cancer management.